Table 7.
Adverse events related to device, procedure, or therapy through 24 months
| AE type | N participants (%) | N events | Resolved (%) | Mild/moderate severity (%) |
|---|---|---|---|---|
| Pain, neuroregulator site | 61 (38) | 78 | 82 | 96 |
| Other | 42 (26) | 52 | 77 | 96 |
| Pain, other | 41 (25) | 50 | 68 | 96 |
| Heartburn/dyspepsia | 42 (26) | 47 | 60 | 100 |
| Pain, abdominal | 23 (14) | 31 | 84 | 100 |
| Nausea | 13 (8) | 18 | 89 | 89 |
| Chest pain | 15 (9) | 16 | 69 | 94 |
| Dysphagia | 14 (9 | 14 | 79 | 100 |
| Eructation/belching | 14 (9) | 14 | 71 | 100 |
| Incision pain | 12 (7) | 14 | 100 | 100 |
| Bloating, abdominal | 7 (4) | 9 | 78 | 100 |
| Constipation | 8 (5) | 8 | 88 | 88 |
| Cramps, abdominal | 8 (5) | 8 | 50 | 100 |
| Wound redness or irritation | 8 (5) | 8 | 100 | 100 |
| Emesis/vomiting | 6 (4) | 8 | 100 | 88 |
Only adverse events attributed by the investigator to the device, procedure, or therapy that occurred in at least 5 % of vBloc group participants are displayed